Patterns and time of recurrence after complete resection of esophageal cancer

Masahiko Sugiyama, Masaru Morita, Rintaro Yoshida, Koji Ando, Akinori Egashira, Ohga Takefumi, Hiroshi Saeki, Eiji Oki, Yoshihiro Kakeji, Yoshihisa Sakaguchi, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)

Abstract

Purpose The results and outcomes of surgical resection for esophageal carcinoma have improved remarkably in recent years; however, recurrence still frequently develops, even after complete resection. The purpose of this study is to clarify the characteristics of recurrence in this patient population. Methods Among 208 patients, who underwent R0 resection for esophageal carcinoma, recurrence developed in 61. Clinical data were available for 56 of these patients, who were the subjects of this study. We evaluated the time, patterns, and treatment of recurrence in these patients. Results Recurrence developed within 1 and 2 years after esophagectomy in 71 and 84% of the patients, respectively, and was classified as loco-regional (54%), hematogenous (36%), or mixed type (10%). The prognosis of patients with loco-regional recurrence tended to be better than that of those with distant metastasis, although the difference was not significant (P = 0.088). Patients with recurrence treated by chemotherapy alone or multimodal therapy, such as radiation or surgery combined with systemic chemotherapy, survived significantly longer than those with untreatable recurrence (P = 0.016). Conclusion These findings reinforce the importance of careful follow-up for both loco-regional and hematogenous recurrence after esophagectomy, particularly during the first 2 years.

Original languageEnglish
Pages (from-to)752-758
Number of pages7
JournalSurgery today
Volume42
Issue number8
DOIs
Publication statusPublished - Aug 2012

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint

Dive into the research topics of 'Patterns and time of recurrence after complete resection of esophageal cancer'. Together they form a unique fingerprint.

Cite this